Search
Tovecimig
go.drugbank.com/drugs/DB30220InvestigationalNOV1501 is a biologic drug. … NOV1501 is under investigation in clinical trial NCT03292783 (This is a Study to Evaluate the Safety and Tolerability of the Study Drug ABL001, and to Determine the Maximum Tolerated Dose and/or Recommended
ARI-0001
go.drugbank.com/drugs/DB30635InvestigationalARI-0001 is a biologic drug. ARI-0001 is under investigation in clinical trial NCT05641428 (Comparison of Point-of-care Produced CAR T-cell with Commercial CAR T-cells in Patients with R/R LBCL).
Triplizumab
go.drugbank.com/drugs/DB30669Investigationaltriplizumab is a biologic drug. triplizumab is under investigation in clinical trial NCT06486220 (PFLL Combined With PD-1 Antibody With or Without FMT for Oligometastatic NPC,a Phase III ,Open, Randomized
FRAX1036
go.drugbank.com/drugs/DB31834ExperimentalFRAX1036 is a p21-activated kinase (PAK) inhibitor.
GLB-004
go.drugbank.com/drugs/DB32796ExperimentalGLB-004 is a molecular glue degrader targeting ARNT(HIF-1β).[L56125, L56126]
GLB-005
go.drugbank.com/drugs/DB32797ExperimentalGLB-005 is a molecular glue degrader targeting WIZ and is being investigated for treatment of sickle cell disease and β-thalassemia.[L56125, L56126, L56128]
GLB-007
go.drugbank.com/drugs/DB32798ExperimentalGLB-007 is a molecular glue degrader targeting WIZ and ZBTB7A.[L56125, L56126, L56128]
GLB-006
go.drugbank.com/drugs/DB32799ExperimentalGLB-006 is a molecular glue degrader targeting NEK7.[L56125, L56126]